{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphatic+Malformations&page=2",
    "query": {
      "condition": "Lymphatic Malformations",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphatic+Malformations&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T17:59:09.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03652181",
      "title": "CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "CCM",
        "Cavernoma",
        "Cerebral Cavernous Malformation",
        "Cerebral Cavernous Malformations 1",
        "Cerebral Cavernous Malformations 2",
        "Cerebral Cavernous Malformations 3",
        "Cavernous Angioma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2018-08-20",
      "completion_date": "2022-11-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652181"
    },
    {
      "nct_id": "NCT06904612",
      "title": "Using Iodized Salt to Improve Serum Folate, B12 and Iron Levels",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neural Tube Defects",
        "Folic Acid Deficiency",
        "Spina Bifida",
        "Anencephaly-Spina Bifida",
        "B12 Deficiency Vitamin",
        "Anemia",
        "Iron Deficiency Anaemia Due to Dietary Causes"
      ],
      "interventions": [
        {
          "name": "Micronutrient fortified iodized salt",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Hydrocephalus and Neuroscience Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2022-06-01",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06904612"
    },
    {
      "nct_id": "NCT07018401",
      "title": "Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 62,
      "start_date": "2024-05-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 11,
      "location_summary": "San Diego, California • San Francisco, California • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07018401"
    },
    {
      "nct_id": "NCT06789913",
      "title": "A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)",
        "Lymphatic Malformations",
        "Vascular Malformations",
        "PIK3CA Mutation",
        "CLOVES Syndrome",
        "Klippel Trenaunay Syndrome",
        "Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)",
        "Vascular Anomalies"
      ],
      "interventions": [
        {
          "name": "RLY-2608",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2025-06-13",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789913"
    },
    {
      "nct_id": "NCT00576836",
      "title": "Thymus Transplantation Dose in DiGeorge #932",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "DiGeorge Anomaly",
        "DiGeorge Syndrome",
        "Complete DiGeorge Anomaly",
        "Complete DiGeorge Syndrome"
      ],
      "interventions": [
        {
          "name": "Cultured Thymus Tissue Implantation (CTTI)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cultured Thymus Tissue Implantation with Parathyroid Transplantation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2004-09-02",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00576836"
    },
    {
      "nct_id": "NCT03427619",
      "title": "OK432 (Picibanil) in the Treatment of Lymphatic Malformations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphatic Malformations"
      ],
      "interventions": [
        {
          "name": "OK432",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard JH Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 275,
      "start_date": "2005-10-05",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 14,
      "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03427619"
    },
    {
      "nct_id": "NCT00278005",
      "title": "Infection in DiGeorge Following CHD Surgery",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "DiGeorge Syndrome",
        "Congenital Heart Defects"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Healthcare of Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "Up to 15 Years"
      },
      "enrollment_count": 400,
      "start_date": "1998-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-16",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00278005"
    },
    {
      "nct_id": "NCT02718300",
      "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [
        {
          "name": "Parsaclisib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2017-02-08",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718300"
    },
    {
      "nct_id": "NCT01402531",
      "title": "Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "Submucosal Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-07-22",
      "completion_date": "2013-07-27",
      "has_results": true,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01402531"
    },
    {
      "nct_id": "NCT02156115",
      "title": "Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphangiomatosis",
        "Lymphedema",
        "Lymphangiectasia",
        "Pulmonary Lymphangiectasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "2 Years to 90 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-03-23",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-06-25T17:59:09.984Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02156115"
    }
  ]
}